文献速递消化道肿瘤与早癌

NAMPT抑制剂FK866对具有上皮-间质转化标志物的胃癌细胞的选择性细胞毒性源于NAPRT缺失

Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
PubMed 文献 · Gastroenterology · 2018-07-30

研究基于RNA测序数据筛选29株胃癌细胞系,确认7株具有EMT表型,并筛检1345种化合物,发现NAMPT抑制剂FK866可杀死7株EMT特征胃癌细胞系中的6株,而不影响无该特征的胃癌细胞;其机制与NAPRT低表达导致对NAMPT抑制超敏有关,FK866可使EMT亚型胃癌小鼠模型肿瘤在2周内消退。

要点

  • FK866杀死7株EMT特征胃癌细胞系中的6株,不杀无该特征的胃癌细胞。
  • 6株EMT亚型胃癌细胞系NAPRT表达显著低,对NAMPT抑制超敏。
  • 敲低NAPRT使高表达NAPRT的胃癌细胞系对FK866敏感,过表达NAPRT保护缺陷EMT细胞系。

核心结论

  • FK866通过抑制NAPRT缺陷细胞的烟酰胺磷酸核糖转移酶,选择性杀死具有EMT基因表达特征的胃癌细胞。
  • NAPRT表达缺失常通过启动子高甲基化发生,见于许多EMT亚型胃肿瘤。
  • FK866可能用于治疗该亚型肿瘤患者。

研究设计与样本

  • 基于RNA测序分析数据,鉴定29株具有既往与EMT亚型相关基因表达特征的胃癌细胞系。
  • 基于侵袭活性和蛋白标志物确认7株细胞系(Hs746T、SNU1750、MKN1、SK4、SNU484、SNU668和YCC11)的间质表型。
  • 筛检1345种化合物杀死具有EMT特征细胞相较于无该特征细胞系的能力。
  • 在荷GA077肿瘤的BALB/c裸鼠中测试化合物效果,小鼠每日两次腹腔注射化合物或溶媒对照,持续24天,监测肿瘤生长。
  • 对942例胃癌组织进行免疫组化分析,研究EMT标志物与蛋白表达模式的关联。

主要发现

  • FK866杀死7株具有EMT相关基因表达特征的胃癌细胞系中的6株,但不杀死无该特征的胃癌细胞。
  • 6株EMT亚型胃癌细胞系表达显著低水平的烟酸磷酸核糖转移酶(NAPRT),使细胞对烟酰胺磷酸核糖转移酶抑制超敏。
  • 表达较高水平NAPRT的胃癌细胞系(无论EMT标志物如何)在敲低NAPRT后对FK866敏感,而在缺陷EMT细胞系中过表达NAPRT可保护其免受FK866介导的毒性。
  • 给予荷GA077细胞(EMT亚型人胃癌肿瘤)肿瘤的裸鼠FK866导致2周内肿瘤消退;FK866不影响无EMT表达特征的MKN45细胞肿瘤生长。
  • NAPRT缺失可能通过稳定β-连环蛋白促进EMT。

关键数值与推荐

  • 筛检1345种化合物,FK866杀死7株EMT特征胃癌细胞系中的6株。
  • FK866使荷GA077肿瘤裸鼠在2周内肿瘤消退,对MKN45肿瘤无影响。
  • 942例胃癌组织中EMT基因表达特征与较低NAPRT水平相关。

临床怎么用

  • 作者认为FK866可能用于治疗具有EMT基因表达特征亚型的胃癌患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Markers of the epithelial-to-mesenchymal transition (EMT) in gastric tumor tissues are associated with poor patient outcomes. We performed a screen to identify pharmacologic compounds that kill gastric cancer cells with EMT-associated gene expression patterns and investigate their mechanisms. METHODS: We identified 29 gastric cancer cell lines with a gene expression signature previously associated with an EMT subtype, based on data from RNA sequence analyses, and confirmed the mesenchymal phenotypes of 7 lines (Hs746T, SNU1750, MKN1, SK4, SNU484, SNU668, and YCC11), based on invasive activity and protein markers. We screened 1,345 compounds for their ability to kill cells with the EMT signature compared with cell lines without this pattern. We tested the effects of identified compounds in BALB/c nude mice bearing GA077 tumors; mice were given intraperitoneal injections of the compound or vehicle (control) twice daily for 24 days and tumor growth was monitored. Proteins associated with the toxicity of the compounds were overexpressed in MKN1 and SNU484 cells or knocked down in MKN45 and SNU719 using small interfering RNAs. We performed immunohistochemical analyses of 942 gastric cancer tissues and investigated associations between EMT markers and protein expression patterns. RESULTS: The nicotinamide phosphoribosyltransferase inhibitor FK866 killed 6 of 7 gastric cancer cell lines with EMT-associated gene expression signatures but not gastric cancer cells without this signature. The 6 EMT-subtype gastric cell lines expressed significantly low levels of nicotinic acid phosphoribosyltransferase (NAPRT), which makes the cells hypersensitive to nicotinamide phosphoribosyltransferase inhibition. Gastric cell lines that expressed higher levels of NAPRT, regardless of EMT markers, were sensitized to FK866 after knockdown of NAPRT, whereas overexpression of NAPRT in deficient EMT cell lines protected them from FK866-mediated toxicity. Administration of FK866 to nude mice with tumors grown from GA077 cells (human gastric cancer tumors of the EMT subtype) led to tumor regression in 2 weeks; FK866 did not affect tumors grown from MKN45 cells without the EMT expression signature. Loss of NAPRT might promote the EMT, because it stabilizes β-catenin. We correlated the EMT gene expression signature with lower levels of NAPRT in 942 gastric tumors from patients; we also found lower levels of NAPRT mRNA in colorectal, pancreatic, and lung adenocarcinoma tissues with the EMT gene expression signature. CONCLUSIONS: FK866 selectively kills gastric cancer cells with an EMT gene expression signature by inhibiting nicotinamide phosphoribosyltransferase in cells with NAPRT deficiency. Loss of NAPRT expression, frequently through promoter hypermethylation, is observed in many gastric tumors of the EMT subtype. FK866 might be used to treat patients with tumors of this subtype.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Lee J, Kim H, Lee JE, et al. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. Gastroenterology. 2018. PMID: 29775598. doi:10.1053/j.gastro.2018.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。